Innovations in Malaria Vaccine Development (IMV)

archived

USAID is seeking to enhance our malaria vaccine investments through a collaborative design process. The goal of USAID’s Malaria Vaccine Development Program (MVDP) is to demonstrate the proof of concept of a vaccine to reduce morbidity and mortality due to malaria caused by infection with Plasmodium falciparum. Target malaria vaccine end characteristics will include at least 75% efficacy and evidence of affordability. USAID intends to support efforts towards vaccines that have the potential to directly protect recipients against disease caused by P. falciparum such as vaccines that target the pre-erythrocytic (sporozoite and liver stage) and erythrocytic stages of the life cycle. The purpose of this Addendum is to solicit Expressions of Interest (EOI) for novel and innovative approaches to malaria vaccine development that would encompass preclinical development through proof of principle clinical studies to motivate advanced development of a deployable, effective malaria vaccine.

High